LncRNA FGD5‐AS1 can be predicted as therapeutic target in oral cancer

Abstract

Background Long non‐coding RNAs (lncRNAs) have been extensively studied to participate in the carcinogenesis of various tumors. LncRNA FGD5‐AS1 has been studied as an oncogene in several cancers; however, the role it plays in oral squamous cell carcinoma (OSCC) still remains unclear. Methods Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to assess relevant RNAs expression. CCK‐8 and colony formation were combined to investigate cell proliferation. Flow cytometry was implemented to test the apoptosis of cell. Wound healing assay and transwell assays were conducted to investigate cell migration and invasion. Western blot assay was conducted to measure relevant protein expression. Results FGD5‐AS1 expression was aberrantly up‐regulated in OSCC tissue and cells. FDG5‐AS1 up‐regulation induced USP21 overexpression advances OSCC development. Knockdown of FGD5‐AS1 inhibited cell growth, migration, and invasion, yet promoted apoptosis. Conclusion FGD5‐AS1 regulates OSCC via competitively binding to miR‐520b against USP21. It could become a potential diagnostic biomarker for OSCC.

Identification of hsa_circ_0039053 as an up-regulated and oncogenic circRNA in hepatocellular carcinoma via the miR-637-mediated USP21 activation

“…Xu et al showed that the USP21/YY1/SNHG16 axis enhances the progression of NSCL 28 . A study by Liu et al found that lncRNA FGD5-AS1 regulates oral squamous cell carcinoma progression by interacting with the miR-520b/USP21 axis 29 . In line with these reports, we found that USP21 was raised in HCC and promoted HCC progression by targeting miR-637.…”

Long Non-coding RNA FGD5-AS1 Regulates Cancer Cell Proliferation and Chemoresistance in Gastric Cancer Through miR-153-3p/CITED2 Axis

“…Thus, our data indicated that FGD5-AS1 might be an oncogenic transcript in gastric cancer. This finding is certainly not surprising, as FGD5-AS1 was demonstrated to be overexpressed and to promote cancer cell maturation and metastasis in other human cancers, including colorectal cancer, lung cancer, and oral cancer ( Li et al, 2019 ; Fan et al, 2020 ; Liu et al, 2020 ). However, our study is the first to report an aberrant expression and functional role of FGD5-AS1 in gastric cancer, further expending the understanding of overall epigenetic regulation of FGD5-AS1 in human cancer research.…”

“…Moreover, several groups of lncRNAs had been identified to be closely associated with human gastric cancer ( Li et al, 2014 , 2016 ). Among them, lncRNA of FYVE RhoGEF And PH Domain Containing 5 Antisense RNA 1 (FGD5-AS1) had been shown to be overexpressed, possibly acting as an oncogenic promotor in oral cancer, colorectal cancer, and lung cancer ( Li et al, 2019 ; Fan et al, 2020 ; Liu et al, 2020 ). However, the expression profile and molecular function of FGD5-AS1 in human gastric cancer have never been elucidated.…”

<p>Long-Noncoding RNA FGD5-AS1 Enhances the Viability, Migration, and Invasion of Glioblastoma Cells by Regulating the miR-103a-3p/TPD52 Axis</p>

“…11 FYVE, RhoGEF, and PH domain containing 5 antisense RNA 1 (FGD5-AS1) has been found to be involved in several human malignancies. For instance, Ding et al 12 speculated FGD5-AS1 as a plausible therapeutic target for colorectal cancer, and Liu et al 13 revealed the ability of FGD5-AS1 to facilitate the progression of oral squamous cell carcinoma by targeting miR-520b. Moreover, FGD5-AS1 has been reported to accelerate the proliferation of non-small cell lung carcinoma (NSCLC) cells by regulating the hsa-miR-107/fibroblast growth factor receptor-like 1 (FGFRL1) axis.…”